VRON-0300 / Virion Therap - LARVOL DELTA

Ocean Biomedical (NASDAQ: OCEA) Announces Positive Preclinical Oncology Data for VRON-0300, Presented at SITC 2023 Annual Meeting, and Clinical Updates by 50/50 Joint Venture Partner Virion Therapeutics (GlobeNewswire) - "Ocean Biomedical, Inc...today announced that its joint venture partner, Virion Therapeutics...recently presented highly compelling preclinical oncology data at the annual meeting of the Society for Immunotherapy of Cancer, SITC 2023....These new data demonstrate complete and highly reproducible tumor clearance, and protection upon tumor rechallenge, months after animals cleared their initial tumors. A markedly improved immunogenicity was also demonstrated, with a 10-fold increase in T cell responses.VRON-0300 IND-enabling activities are underway, with the goal of filing its first IND within the next 9 months."

IND • Preclinical • Oncology